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Synthetic Procedures. 
 
Synthesis of LMn3(PhPz)3OMn (4). In the glovebox, to a stirring solution of [LMn3(PhPz)3OMn][OTf]2 
(37.0 mg, 20.4 µmol) in MeCN (4 mL) was added decamethylcobaltocene (CoCp*2; 13.7 mg, 41.7 µmol) 
in MeCN (1 mL). Upon addition, a yellow solid immediately precipitated. After two hours, the solid was 
collected, washed with MeCN (5 mL) and THF (5 mL), and dried under reduced pressure to yield the 
putative LMn3(PhPz)3OMn as a yellow solid. Yield 11.4 mg (40 %). Note, the insolubility of this 
compound in common organic solvents precluded us from performing extensive characterization. 
 
Synthesis of [LMn3(PhPz)3OMn][BPh4]1 (3’). In the glovebox, to a suspension of LMn3(PhPz)3OMn 
(197 mg, 130.0 µmol) in MeCN (4 mL) was added AgBPh4 (56.1 mg, 132 µmol) in MeCN (2 mL). After 
one hour, the suspension changed color from yellow to purple-gray. The mixture was stirred for an 
additional two hours, where after the solvent was removed under reduced pressure. The resulting solid 
was stirred in DME (10 mL) and filtered over a pad of Celite on top a coarse porosity glass frit. The 
purple solid was washed with DME (ca. 20 mL) until the filtrate became colorless. The red-brown filtrate 
was discarded, and the purple brown solid was eluted with a minimal of CH2Cl2. The solvent was 
removed under reduced pressure to yield [LMn3(PhPz)3OMn][BPh4]1 as a purple brown solid. Yield 110 
mg (46 %). The 1H NMR of 3’ is identical to that of 3 (Figure S5). Note: using other counter ions did not 
result in the formation of crystals amenable for X-ray diffraction. 
 
Synthesis of [LMn3(PhPz)2(OArPz)OMn][BPh4]1 (6’). In the glovebox, to a thawing suspension of 
[LMn3(PhPz)3OMn][BPh4]1 (378 mg, 206 µmol) in MeCN (20 mL) was added a thawing solution of 
NaOArPzH (42.5 mg, 226 µmol) in MeCN (1 mL). The mixture was stirred for 16 hours and a maroon 
slurry formed during the course of the reaction. Hereafter, AgBPh4 (96.5 mg, 222 µmol) in MeCN (2 mL) 
was added, and the mixture was stirred for another 2 hours. During the course of the reaction the color 
changed from maroon, to red brown. The solvent was removed under reduced pressure, and the solids 
dissolved in CH2Cl2 and filtered over a Celite pad on top of a medium porosity glass frit. The filtrate was 
collected and the solvent removed under reduced pressure to yield [LMn3(PhPz)2(OArPz)OMn][BPh4]1 as 
a purple-black solid. Yield 378 mg (98 %). X-ray quality crystals were obtained by diffusing diethyl ether 
into a concentrated solution of 6’ in acetonitrile. The 1H NMR spectrum of 6’ is identical to that of 6 
(Figure S12). Note, that addition of PhIO to 3’ also resulted in the formation of 6’. However, crystals 
obtained from this reaction mixture showed to be a mixture of 3’ and 6’ by X-ray crystallography (data 
not shown). One electron-oxidation of 6’ did not give crystals suitable for X-ray diffraction. 
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Figure S1. 1H NMR (300 MHz) spectrum of LMn3(OAc)(OTf)2 in CD2Cl2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2. 1H NMR (300 MHz) spectrum of [LMn3(PhPz)3ONa][OTf]1 (1) in CD2Cl2. 
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Figure S3. 1H NMR (300 MHz) spectrum of [LMn3(PhPz)3OMn][OTf]2 (2) in CD2Cl2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4. 1H NMR (300 MHz) spectrum of [LMn3(PhPz)3OMn][OTf]1 (3) in CD2Cl2. 
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Figure S5. Comparison of the 1H NMR (300 MHz) spectrum of [LMn3(PhPz)3OMn][OTf]1 (3) and 
[LMn3(PhPz)3OMn][BPh4]1 (3’) in CD2Cl2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S6. 1H NMR (300 MHz) spectrum of [LMn3(PhPz)2(OArPz)OMn][OTf]2 (5) in CD2Cl2. 
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Figure S7. 1H NMR (300 MHz) spectrum of the crude reaction mixture upon treating 
[LMn3(PhPz)3OMn][OTf]2 (2) with PhIO. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S8. Comparison of the 1H NMR (300 MHz) spectrum of the crude reaction mixture with the NMR 
spectrum of independently synthesized [LMn3(PhPz)2(OArPz)OMn][OTf]2 (5). 
	 S9	
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S9. 1H NMR (300 MHz) spectrum of [LMn3(PhPz)2(OArPz)OMn][OTf]1 (6) in CD2Cl2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S10. 1H NMR (300 MHz) spectrum of [LMn3(PhPz)2(OArPz)OMn][BPh4]1 (6’) in CD2Cl2. 
	 S10	
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S11. 1H NMR (300 MHz) spectrum of the crude reaction mixture upon treating 
[LMn3(PhPz)3OMn][OTf]1 (3) with PhIO. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S12. Comparison of the 1H NMR (300 MHz) spectrum of the crude reaction mixture with the 
NMR spectra of independently synthesized [LMn3(PhPz)2(OArPz)OMn][OTf]1 (6) and 
[LMn3(PhPz)2(OArPz)OMn][BPh4]1 (6’). 
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Figure S13. 1H NMR (300 MHz) spectrum of [LMn3(F2ArPz)3ONa][OTf]1 (7) in CD2Cl2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S14. 1H NMR (300 MHz) spectrum of [LMn3(F2ArPz)3OMn][OTf]2 (8) in CD2Cl2. 
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Figure S15. 1H NMR (300 MHz) spectrum of [LMn3(F2ArPz)3OMn][OTf]1 (9) in CD2Cl2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S16. 1H NMR (300 MHz) spectrum of the crude reaction mixture upon treating 
[LMn3(F2PhPz)3OMn][OTf]2 (8) with PhIO. 
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Figure S17. 1H NMR (300 MHz) spectrum of the crude reaction mixture upon treating 
[LMn3(PhPz)3OMn][OTf]1 (9) with PhIO. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S18. ESI mass spectrum of an aliquot of the reaction of LMn3(OAc)(OTf)2, with NaPhPz, and 
PhIO, showing the formation of [LMn3(PhPz)3ONa][OTf]1 (1; m/z 1488.1). 
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Figure S19. ESI-MS spectrum of [LMn3(PhPz)3OMn][OTf]2 (2; m/z 760.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S20. ESI-MS spectrum of [LMn3(PhPz)3OMn][OTf]1 (3; m/z 1520.1). 
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Figure S21. ESI-MS spectrum of the crude reaction mixture upon treating [LMn3(PhPz)3OMn][OTf]2 (2) 
with PhIO. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S22. Comparison of the ESI-MS spectrum of the crude reaction mixture with the ESI-MS 
spectrum of independently synthesized [LMn3(PhPz)2(OArPz)OMn][OTf]2 (5). 
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Figure S23. ESI-MS spectrum of the crude reaction mixture upon treating [LMn3(PhPz)3OMn][OTf]1 (3) 
with PhIO after three hours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S24. Comparison of the ESI mass spectrum of the crude reaction mixture with the ESI-MS 
spectrum of independently synthesized [LMn3(PhPz)2(OArPz)OMn][OTf]1 (6). 
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Figure S25. ESI-MS spectrum of an aliquot of the reaction of LMn3(OAc)(OTf)2, with NaF2ArPz and 
PhIO, showing the formation of [LMn3(F2ArPz)3ONa][OTf]1 (7; m/z 1595.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S26. ESI-MS spectrum of [LMn3(F2ArPz)3OMn][OTf]2 (8; m/z 814.3). 
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Figure S27. ESI mass spectrum of [LMn3(F2ArPz)3OMn][OTf]1 (9; m/z 1627.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S28. ESI-MS spectrum of the crude reaction mixture upon treating [LMn3(F2ArPz)3OMn][OTf]2 
(8) with PhIO. 
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Figure S29. ESI-MS spectrum of the crude reaction mixture upon treating [LMn3(F2ArPz)3OMn][OTf]1 
(9) with PhIO. 
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Figure S30. Crystal structure of [LMn3(PhPz)3OMn][OTf]2 (2). Thermal ellipsoids are shown at the 50% 
probability level. Hydrogen atoms, outer sphere counter ions, and co-crystallized solvents molecules are 
not shown for clarity. 
 
Special refinement details for complex 2. Compound [LMn3(PhPz)3OMn][OTf]2 (2) crystallizes in the 
orthorhombic space group P212121 with one molecule in the asymmetric unit along with two triflate 
anions, 1.18 molecules of acetonitrile and 0.82 molecules of diethyl ether. The co-crystallized diethyl 
ether molecule is disordered with an acetonitrile molecule and refined freely as a two-component disorder 
with occupancies of 0.18 (acetonitrile) and 0.82 (diethyl ether). The disordered solvent molecules were 
refined with direct distance restraints and similarity restraints on the 1,2- and 1,3-distances and 
displacement parameters, as well with the help of enhanced rigid bond restraints for anisotropic 
displacement parameters. The 1,2- and 1,3-distances of the remaining acetonitrile molecule was refined 
with the help of direct distance restraints, with the anisotropic displacement parameters refined with help 
enhanced rigid bond restraints. The crystal was racemically twinned, and the twin ratio was refined freely 
converging at a value of 0.130(14). 
 
 
 
 
	 S21	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S31. Crystal structure of [LMn3(PhPz)3OMn][OTf]1 (3). Thermal ellipsoids are shown at the 50% 
probability level. Hydrogen atoms, outer sphere counter ions, and co-crystallized solvents molecules are 
not shown for clarity. 
 
Special refinement details for complex 3. Compound [LMn3(PhPz)3OMn][OTf]1 (3) crystallizes in the 
triclinic space group P-1 with one molecule in the asymmetric unit along with one triflate anion, one 
molecule of acetonitrile and half a molecule of diethyl ether. The co-crystallized diethyl ether molecule is 
close to a special position and was refined the help of direct distance restraints and similarity restraints on 
1,2- and 1,3-distances and displacement parameters, as well with the help of enhanced rigid bond 
restraints for anisotropic displacement parameters. The 1,2- and 1,3-distances for all acetonitrile 
molecules were refined with the help of direct distance restraints, and the anisotropic displacement 
parameters were refined with enhanced rigid bond restraints. 
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Figure S32. Crystal structure of [LMn3(PhPz)2(OArPz)OMn][BPh4]1 (6’). Thermal ellipsoids are shown 
at the 50% probability level. Hydrogen atoms, outer sphere counter ions, and co-crystallized solvents 
molecules are not shown for clarity. 
 
Special refinement details for complex 6’. Compound [LMn3(PhPz)2(OArPz)OMn][BPh4]1 (6’) 
crystallizes in the monoclinic space group P21/c with one molecule in the asymmetric unit along with one 
tetraphenylborate anion, and one molecule of diethyl ether. The co-crystallized diethyl ether molecule 
was refined the help of direct distance restraints and similarity restraints on 1,2- and 1,3-distances and 
displacement parameters, as well with the help of enhanced rigid bond restraints for anisotropic 
displacement parameters.  
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Figure S33. Crystal structure of [LMn3(F2PhPz)3OMn][OTf]2 (8). Thermal ellipsoids are shown at the 
50% probability level. Hydrogen atoms, outer sphere counter ions, and co-crystallized solvents molecules 
are not shown for clarity. 
 
Special refinement details for complex 8. Compound [LMn3(F2PhPz)3OMn][OTf]2 (8) crystallizes in 
the monoclinic space group P21/c with one molecule in the asymmetric unit along with two triflate 
anions, one molecule of acetonitrile and half a molecule of 3-(2,6-difluorophenyl)-1H-pyrazole. One of 
the triflate anions is disordered and was modelled as a three-component disorder with occupancies of 
0.26, 0.27, and 0.47. The disordered triflate anions were refined with the help of similarity restraints on 
the 1,2- and 1,3-distances and displacement parameters, as well as enhanced rigid bond restraints for 
anisotropic displacement parameters. The acetonitrile molecules (both at half occupancy) were refined 
with the help of similarity restraints on the 1,2- and 1,3-distances and displacement parameters, while 
restraining the 1,2- and 1,3-distances with the help of direct distance restraints and enhanced rigid bond 
restraints for anisotropic displacement parameters. The 3-(2,6-difluorophenyl)-1H-pyrazole is hydrogen 
bonded to one of the triflate anions, and refined freely to ca. 0.50 occupancy, and was subsequently 
restrained at that value.  
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Figure S34. Crystal structure of [LMn3(F2PhPz)3OMn][OTf]1 (9) Thermal ellipsoids are shown at the 
50% probability level. Hydrogen atoms, outer sphere counter ions, and co-crystallized solvents molecules 
are not shown for clarity. 
 
Special refinement details for complex 9. Compound [LMn3(F2PhPz)3OMn][OTf]1 (9) crystallizes in 
the monoclinic space group P21/n with one molecule in the asymmetric unit along with one triflate anion, 
and 1.5 molecules of diethyl ether. The triflate anions is disordered and was modelled as a two-
component disorder with occupancies of 0.20, and 0.80. The disordered triflate was refined with the help 
of similarity restraints on the 1,2- and 1,3-distances and displacement parameters, as well as enhanced 
rigid bond restraints for anisotropic displacement parameters. The first diethyl molecule (full occupancy) 
is disordered at oxygen, and refined as a two-component disorder with occupancies of 0.26 and 0.74. The 
second diethyl ether molecule (half occupancy) is close to a special position. The co-crystallized diethyl 
ether molecules were refined with the help of similarity restraints on the 1,2- and 1,3-distances and 
displacement parameters, while restraining the 1,2- and 1,3-distances with the help of direct distance 
restraints and enhanced rigid bond restraints for anisotropic displacement parameters.  
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Table S1. Crystal and refinement data for complexes 2, 3, and 6’. 
 Complex 2 Complex 3 Complex 6’ 
CCDC 1548241 1548240 1548243 
Empirical 
formula C93.64H74.73F6Mn4N14.18O10.82S2 C89H68F3Mn4N13O7.5S C114H92BMn4N13O6 
Formula 
weight (g/mol) 1969.57 1748.38 1970.57 
T (K) 100 100 100 
Radiation MoKα (λ = 0.71073) MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
a (Å) 14.8196(4) 12.4071(4) 14.546(2) 
b (Å) 16.7019(4) 16.0480(6) 36.069(6) 
c (Å) 35.3384(8) 20.3445(7) 17.451(3) 
α (deg) 90 78.6850(10) 90 
β (deg) 90 78.8770(10) 92.651(6) 
γ (deg) 90 84.4930(10) 90 
V (Å3) 8746.8(4) 3890.3(2) 9146(2) 
Z 4 2 4 
Cryst. syst. Orthorhombic  Triclinic Monoclinic 
Space group P212121 P-1 P21/c 
ρcalcg (cm3) 1.496 1.493  
2 σ range (deg) 4.61 to 61.084 5.066 to 61.228 1.431 
Crystal 
size/mm 0.1 × 0.1 × 0.1 0.33 × 0.16 × 0.05 0.1 × 0.1 × 0.1 
µ (mm-1) 0.695 0.737 0.608 
GOF 1.030 1.049 1.062 
R1, wR2 (I> 
2σ (I)) R1 = 0.0556, wR2 = 0.1040 R1 = 0.0463, wR2 = 0.1220 R1 = 0.0818, wR2 = 0.2078 
 
Table S2. Crystal and refinement data for complexes 8, and 9. 
 Complex 8 Complex 9 
CCDC 1548239 1548242 
Empirical 
formula C94.5H62.5F13Mn4N15O10S2 C91H69F9Mn4N12O8.5S 
Formula weight 
(g/mol) 2098.97 1889.40 
T (K) 100 100 
Radiation MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
a (Å) 22.649(3) 12.1673(6) 
b (Å) 17.5953(19) 26.7525(13) 
c (Å) 24.208(3) 25.1112(12) 
α (deg) 90 90 
β (deg) 97.034(3) 98.352(2) 
γ (deg) 90 90 
V (Å3) 9575.0(18) 8087.1(7) 
Z 4 4 
Cryst. syst. Monoclinic Monoclinic 
Space group P21/c P21/n 
ρcalcg (cm3) 1.456 1.552 
2 σ range (deg) 1.812 to 49.724 4.25 to 61.152 
Crystal 
size/mm 0.1 × 0.1 × 0.1 0.2 × 0.1 × 0.1 
µ (mm-1) 0.650 0.726 
GOF 1.075 1.077 
R1, wR2 (I> 2σ 
(I)) R1 = 0.0806, wR2 = 0.2359 R1 = 0.0533, wR2 = 0.1061 
 
